Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 19/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7605106 | 1.00 | NPY2R (0.68) | NPY2RMEN1MAPTKMT2A | |
| SCHEMBL13873608 | 0.83 | NPY2R (0.73) | NPY2RMEN1MAPTKMT2A | |
| SCHEMBL8735896 | 0.83 | NPY2R (0.73) | NPY2RMEN1MAPTKMT2A | |
| SCHEMBL7599095 | 0.81 | NPY2R (1.00) | NPY2R | |
| SCHEMBL13873647 | 0.80 | NPY2R (0.75) | NPY2RMEN1MAPTKMT2A | |
| SCHEMBL5128192 | 0.78 | NPY2R (0.44) | NPY2RMEN1MAPTKMT2A | |
| SCHEMBL5128198 | 0.78 | ALDH1A1 (0.47) | NPY2RMAPT | |
| SCHEMBL8737930 | 0.75 | NPY2R (0.63) | NPY2RMEN1MAPTKMT2A | |
| SCHEMBL5080044 | 0.74 | NPY2R (0.68) | NPY2R | |
| SCHEMBL5083776 | 0.74 | NPY2R (0.69) | NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | NPY2R 1/4885MEN1 3277/4885MAPT 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.